Staar back on PMA (pre-market approval) track with Visian?
This article was originally published in Clinica
Executive Summary
Ophthalmic company Staar Surgical may soon see an end to its long struggle to get approval for its Visian implantable contact lens (ICL). The FDA has determined that the device is approvable, following a review of the firm's pre-market approval (PMA) application for the product. However, the final thumbs up will only be given if the company passes an FDA manufacturing facilities inspection. Investors welcomed this news by giving the company's stocks a much-needed boost, as Staar's share price closed at an all-month high of $5.28 on July 29, the day after the announcement.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.